MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
MIMEDX Group, Inc. (Nasdaq: MDXG) announced its participation in the Symposium on Advanced Wound Care (SAWC) Fall meeting from October 2-5 in Las Vegas. The company will showcase its allograft portfolio and latest scientific and clinical evidence. Key events include:
1. A sponsored lunch symposium on the evolving wound care landscape.
2. A hands-on skills lab focusing on managing lower extremity wounds.
3. Seven accepted poster presentations covering clinical and scientific research.
MIMEDX will also have representatives at booth 511 to discuss product news and clinical information. Dr. John R. Harper, MIMEDX Chief Scientific Officer, emphasized the company's leadership in expanding understanding of placental tissue's characteristics and potential clinical benefits, particularly in inflammation and epithelialization.
MIMEDX Group, Inc. (Nasdaq: MDXG) ha annunciato la sua partecipazione al Simposio sulla Cura Avanzata delle Ferite (SAWC) incontro autunnale dal 2 al 5 ottobre a Las Vegas. L'azienda presenterà il suo portafoglio di allografi e le ultime evidenze scientifiche e cliniche. Gli eventi principali includono:
1. Un simposio per il pranzo sponsorizzato sull'evoluzione del panorama della cura delle ferite.
2. Un laboratorio pratico focalizzato sulla gestione delle ferite degli arti inferiori.
3. Sette presentazioni di poster accettate che coprono ricerca clinica e scientifica.
MIMEDX avrà anche rappresentanti allo stand 511 per discutere delle novità sui prodotti e delle informazioni cliniche. Il Dr. John R. Harper, Chief Scientific Officer di MIMEDX, ha sottolineato la leadership dell'azienda nell'espandere la comprensione delle caratteristiche del tessuto placentare e dei potenziali benefici clinici, in particolare in relazione all'infiammazione e all'epitelializzazione.
MIMEDX Group, Inc. (Nasdaq: MDXG) anunció su participación en el Simposio sobre el Cuidado Avanzado de Heridas (SAWC) reunión de otoño del 2 al 5 de octubre en Las Vegas. La empresa mostrará su portafolio de aloinjertos y las últimas evidencias científicas y clínicas. Los eventos clave incluyen:
1. Un simposio de almuerzo patrocinado sobre la evolución del panorama del cuidado de heridas.
2. Un laboratorio práctico centrado en la gestión de heridas en extremidades inferiores.
3. Siete presentaciones de carteles aceptadas que cubren investigación clínica y científica.
MIMEDX también tendrá representantes en el stand 511 para discutir noticias sobre productos e información clínica. El Dr. John R. Harper, Director Científico de MIMEDX, enfatizó el liderazgo de la empresa en la expansión de la comprensión de las características del tejido placentario y los posibles beneficios clínicos, particularmente en inflamación y epitelización.
MIMEDX Group, Inc. (Nasdaq: MDXG)는 10월 2일부터 5일 사이에 라스베이거스에서 열리는 고급 상처 관리 심포지엄(SAWC) 가을 회의에 참여한다고 발표했습니다. 이 회사는 자신의 동종 이식 포트폴리오와 최신 과학 및 임상 증거를 소개할 것입니다. 주요 행사에는:
1. 진화하는 상처 관리 풍경에 대한 후원 점심 심포지엄.
2. 하지 상처 관리에 중점을 둔 실습 기술 실험실.
3. 임상 및 과학 연구를 다룬 7개의 포스터 발표가 포함됩니다.
MIMEDX는 또한 511번 부스에서 제품 뉴스 및 임상 정보를 논의할 대표자들을 보유할 것입니다. MIMEDX의 최고 과학 책임자인 드. 존 R. 하퍼는 플래센탈 조직의 특성과 잠재적 임상 이점, 특히 염증 및 상피화에 대한 이해를 확장하는 회사의 주도성을 강조했습니다.
MIMEDX Group, Inc. (Nasdaq: MDXG) a annoncé sa participation au Symposium sur les Soins des Plaies Avancés (SAWC) réunion d'automne du 2 au 5 octobre à Las Vegas. L'entreprise présentera son portefeuille d'allogreffes et les dernières preuves scientifiques et cliniques. Les événements clés comprennent :
1. Un symposium-déjeuner sponsorisé sur l'évolution du paysage des soins des plaies.
2. Un laboratoire pratique axé sur la gestion des plaies des membres inférieurs.
3. Sept présentations d'affiches acceptées couvrant la recherche clinique et scientifique.
MIMEDX aura également des représentants au stand 511 pour discuter des nouvelles sur les produits et des informations cliniques. Le Dr. John R. Harper, directeur scientifique de MIMEDX, a souligné le leadership de l'entreprise dans l'élargissement de la compréhension des caractéristiques du tissu placentaire et de ses avantages cliniques potentiels, notamment en matière d'inflammation et d'épithélialisation.
MIMEDX Group, Inc. (Nasdaq: MDXG) gab bekannt, dass es am Symposium für Fortgeschrittene Wundversorgung (SAWC) Herbsttagung vom 2. bis 5. Oktober in Las Vegas teilnehmen wird. Das Unternehmen wird sein Allograft-Portfolio und die neuesten wissenschaftlichen und klinischen Erkenntnisse präsentieren. Zu den wichtigen Veranstaltungen gehören:
1. Ein gesponsertes Mittagssymposium zur Entwicklung der Wundversorgungslandschaft.
2. Ein praktisches Fertigkeitslabor, das sich auf das Management von Wunden der unteren Extremitäten konzentriert.
3. Sieben angenommene Posterpräsentationen zu klinischer und wissenschaftlicher Forschung.
MIMEDX wird auch Vertreter am Stand 511 haben, um Produktneuheiten und klinische Informationen zu besprechen. Dr. John R. Harper, Chief Scientific Officer von MIMEDX, betonte die Führungsrolle des Unternehmens bei der Erweiterung des Verständnisses der Eigenschaften von Plazentagewebe und potenziellen klinischen Vorteilen, insbesondere in Bezug auf Entzündungen und Epithelisierung.
- MIMEDX is presenting seven accepted clinical and scientific posters at SAWC Fall, demonstrating strong research output
- The company is sponsoring a lunch symposium and hands-on skills lab, showcasing its industry leadership
- MIMEDX continues to expand its portfolio of clinical and scientific research, reinforcing its market position
- None.
Insights
MIMEDX's participation at SAWC Fall demonstrates their commitment to advancing wound care research and clinical evidence. The company is presenting seven accepted posters, covering both clinical and scientific research on their allograft products. This extensive research portfolio strengthens MIMEDX's position in the advanced wound care market.
Key highlights include:
- Studies on chronic pressure injuries and venous leg ulcers, addressing significant wound care challenges
- Cost-effectiveness analysis of their product for post-Mohs surgery reconstruction
- Scientific research on macrophage response modulation and re-epithelialization promotion
The sponsored lunch symposium and hands-on skills lab provide valuable educational opportunities for healthcare professionals, potentially increasing product adoption. While this news doesn't directly impact financials, it reinforces MIMEDX's scientific leadership and could contribute to long-term market share growth in the
MIMEDX's strong presence at SAWC Fall is a strategic move to reinforce its market position. The company's focus on scientific evidence and clinical data aligns with the industry trend towards evidence-based medicine. This approach can potentially:
- Enhance credibility among healthcare providers
- Support reimbursement decisions by payers
- Differentiate MIMEDX products in a competitive market
The lunch symposium addressing changing practices and payer dynamics is particularly relevant, as it tackles key challenges in the wound care industry. By addressing these issues, MIMEDX positions itself as a thought leader and partner to healthcare providers.
While this event may not have an immediate impact on stock price, it strengthens MIMEDX's long-term competitive position. Investors should monitor for subsequent increases in product adoption rates or new partnerships resulting from these educational initiatives.
Company to Sponsor Lunch Symposium and Hands-On Skills Lab
Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research
MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. SAWC Fall is the largest gathering of advanced wound care industry and healthcare professionals and serves as an educational forum to connect with this global community.
“Our research and clinical teams have continued to extend our leadership in expanding the understanding of placental tissue’s unique characteristics and potential clinical benefits,” said Dr. John R. Harper, Ph.D., MIMEDX Chief Scientific Officer. “At SAWC this year, we are proud to once again highlight new research on our product portfolio in two areas that are key to the wound healing cascade, namely inflammation and epithelialization. We continue striving to lead the field in scientific publications and Level I clinical data. In addition, we are excited to connect with attendees with valuable sessions, including a hands-on skills lab that will provide a deep dive into innovative treatment techniques.”
In addition to the events highlighted below, MIMEDX sales representatives and medical science liaisons will be onsite during exhibit hall hours at booth 511 to discuss the latest product news and clinical information.
Sponsored Lunch Symposium
Wound Care Evolution: Patients Change, Practices Change, Payors Change: Providers Adapt
Date/Time: Thursday, October 3 / 11:40 a.m. – 1:10 p.m. PDT
Faculty: Ehab Sorial, MD, FACS; Naz Wahab, MD, FAAFP, FAPWCA; Dorothy Kurtz Phelan, DPM, D.BFAS, FACFAS; Allyn Forsyth, PhD
Description: This symposium will cover the rapidly changing landscape of wound care, particularly around the use and reimbursement of skin substitutes. As patient populations shift and treatment methodologies evolve, healthcare professionals must stay ahead of the curve to provide optimal care.
Hands-On Skills Lab (CME-Eligible)
Overcoming Challenges in Assessing and Managing Lower Extremity Wounds: Hands-On Workshop
Date/Time: Thursday, October 3 / 1:20 p.m. – 4:40 p.m. PDT
Moderator: Pamela Scarborough, PT, DPT, CWS, FAAWC
MIMEDX Presenter: Randall Spencer
Description: This hands-on workshop will explore innovative treatment techniques for the most common lower extremity wounds. Attendees will engage in experiential learning through product demonstrations of debridement technologies, compression therapy, negative pressure wound therapy, skin substitutes, and more.
Accepted Poster Presentations
The Company is pleased to announce that seven clinical and scientific posters have been accepted and will be on display in the poster hall.
Clinical Research
- Chronic Pressure Injuries: More than Taking the Pressure off with Lyophilized Human Amnion/Chorion Membrane
- Dehydrated Human Amnion Chorion Membrane for Reconstruction of Cutaneous Defects Following Mohs Surgery: A Propensity Score-Matched Comparative Cost-Effectiveness Analysis
- Survey of Patients with Hard-to-Heal Wounds
- The Impacts of Medicaid Status on Venous Leg Ulcer Outcomes
- Pyoderma Gangrenosum: A Light at the End of the Tunnel for an Orphan Disease: Dehydrated Human Amnion/Chorion Membrane
Scientific Research
- Lyophilized Human Amnionic Membrane Modulates the Macrophage Response During Wound Healing
- Tri-Layer Amniotic Membrane Allografts Promotes Re-Epithelialization In Vitro via cJUN Mediated Mechanism
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
FAQ
What events is MIMEDX participating in at SAWC Fall 2024?
What are the key research areas MIMEDX is focusing on for wound healing?
How many posters has MIMEDX had accepted for presentation at SAWC Fall 2024?
When and where is the SAWC Fall meeting taking place for MDXG?
